<DOC>
	<DOCNO>NCT02691156</DOCNO>
	<brief_summary>Most preterm newborn manage phototherapy reverse hyperbilirubinemia intent prevent bilirubin neurotoxicity . A threshold-based relationship specific total bilirubin level need intervention elusive . This likely due biomarkers hemolysis , developmental maturation , concurrent illness , even intervention , may impede bilirubin/albumin binding . The over-prescription phototherapy impact clinical family-centered care , extreme preterm infant , may augment risk mortality . Thus , opportunity individualize phototherapy order reduce use unique . The investigator assemble transdisciplinary team examine critical unanswered question include role bilirubin bind capacity ( BBC ) individual first week life context clinical modifier antecedent domain bilirubin-induced neurologic disorder , include neuro-anatomical , hearing , visual developmental processing impairment . In study , investigator evaluate two new innovative nanotechniques quantify bilirubin load first time context clinical decision algorithm identify risk bilirubin-related neurotoxicity . The investigator anticipate knowledge gain study lead ethically testable hypothesis individualize prescription phototherapy .</brief_summary>
	<brief_title>Bilirubin Binding Capacity Assess Bilirubin Load Preterm Infants</brief_title>
	<detailed_description>The investigator intend first collect simultaneous comprehensive `` acute phase '' measurement TB , BBC , ETCOc , COHbc MPT infant . The investigator seek understand precisely relationship GA , TB , BBC , ETCOc , COHbc level domains BIND . Third , The investigator provide comprehensive database use improve current neonatal BIND screening practice context lower high BBC . The investigator 's work hypothesis exposure modest TB level presence significantly diminish BBC develop neonate result residual deficit one neuroprocessing function ( BIND ) TEA . 1 . Patients ( GA 24 &lt; 34 wks ) enrol . Subject exclusion criterion : Major life-threatening anomaly diagnose inborn error metabolic disorder ; attend physician parent refusal . Clinical data collection : After receive write informed consent , research team complete clinical data form infant demographic . The data form consistent abstract medical record . No additional information collect exploratory study . Population : The entire cohort compromise 60-80 patient . From cohort , 12 at-risk infant impaired BBC match designate low-risk re-recruited follow-up identify evidence BIND 4 outcome variable . Laboratory data : Once inclusion criterion meet , routine neonatal laboratory test clinically order . Each infant test BBC ETCOc least 2 interval ( maximum 4 12h-7d ) rates-of-rise -decrease TB . Subsequent laboratory clinical data pair research data statistical analysis . The investigator compare BIND outcomes TEA 3 mos-corrected age ( &lt; 54 wks PMA ) use re-consented sample size : n=12 high risk decrease BBC versus GA-matched control low risk ( n=12 ) . 2 . Measurements : 0.1-mL whole blood drawn special heparinized tube COHbc determination anticoagulated blood set aside hematofluorometry . Plasma peroxidase UB assay store label without patient identifier . Frozen research sample transport Spectrum Child Health Research ( SCHR ) Lab analyse . 1 . BBC , TB , UB measure directly : 1a . BBC , TB UB 50-μL whole blood use POC hematofluorometry ; TB perform hospital-based clinical laboratory ; UB plasma use peroxidase method ( Arrows device ) . ETCOc determine breathe spontaneously . c. Testing technique outcome variable select at-risk matched control infant : 1 . Screening ABR : Two simultaneously channel consist electrode pair : 1 ) contralateral ipsilateral mastoid prominence ; 2 ) vertex ipsilateral mastoid ; 3 ) vertex contralateral mastoid well identification wave . Insert tubephone earphone use introduce acoustic delay distinguish CM response artifact . Rarefaction click 90 , ( 75 ) , 60 , ( 45 ) , 30 dBnHL deliver monaurally right left ear . RE LE , ≥2 repetition , ≥2,000 sweeps/repetition . Separate record rarefaction condensation click obtain 90 dB . The surface electrical activity amplify x10,000 filtered 30-3,000 Hz . Latencies peak-to-trough amplitude wave CM outer hair cell inner ear ABRs score independently `` mask '' interpreter ( Drs . Oghalia Popelka ) . 2 . Screening Visual Brainstem Responses TEA ( 50-54 wks PMA ) : All infant subcohort evaluate use sVEP technique describe above.68 Electrodes place across back visual cortex , midline 2 cm leave right , reference lead occipital vertex . Thresholds suprathreshold measurement compare control . Further , infant bilirubin cohort serve case series dose response plot determine , compare threshold TB level . Bin average type vision also compare control infant determine whether suprathreshold measure vary significant degree control ( Fig . 3 ) . Evidence study CNS damage suggest low signal amplitude thresholds correlate CNS damage . Support sample size base practical consideration ad hoc sample size calculation . 3 . Neuroimaging brain perform conventional MRI TEA ; routine near-term neuroimaging preterm infant institution . MRI perform unsedated infant , use 3-Tesla platform sequence include Sagittal T1 FLAIR , Axial DWI , T2 FRFSE , FLAIR , GRE , SSFSE , Coronal SSFSE 3D SPGR 30 min . Drs . Barnes Hintz , mask acute phase biomarkers data , interpret image utilizing central reader form include white matter score accord widely use classification system , data regard location , number , size , image characteristic lesion . Dr. Bhutani correlate data acute biomarkers .</detailed_description>
	<mesh_term>Birth Weight</mesh_term>
	<mesh_term>Hyperbilirubinemia</mesh_term>
	<mesh_term>Neurologic Manifestations</mesh_term>
	<mesh_term>Kernicterus</mesh_term>
	<mesh_term>Carbon Monoxide</mesh_term>
	<mesh_term>Bilirubin</mesh_term>
	<criteria>Patients ( GA 24 ≤34 wks ) Major lifethreatening anomaly diagnose inborn error metabolic disorder Attending physician parent refusal</criteria>
	<gender>All</gender>
	<minimum_age>24 Weeks</minimum_age>
	<maximum_age>34 Weeks</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Hematofluorometer</keyword>
</DOC>